Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$1.85 0.07 (3.93%)
2/9/2010 1:53 PM

Gentium S.p.A. (ADR) (GENT)

CAPS Rating:
No stars

A biopharmaceutical company engaged in the research, development and manufacture of drugs to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

GENT doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

15 Outperforms
5 Underperforms
 

All-Stars

9 Outperforms
3 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on GENT are also bullish on:

Members bearish on GENT are also bearish on:

Ticker Tags

Healthcare (711), Biotechnology (220), Aggressive Growth (860), Defensive (1457), Growth (1902), Micro Cap (4701), Distressed (1597)
Suggest a tag

Gentium S.p.A. (ADR) At A Glance

Current Price: $1.85
Last Trade Time: 2/9/2010 1:53 PM
Open: $0.00
Previous Close: $1.78
Daily Range: $1.78 - $1.89
52-Week Range: $0.28 - $4.00
Volume: 7,600
Market Cap: $27.67M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

GENT VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

1

Gentium S.p.A. (ADR) (GENT)

Avatar zzlangerhans (99.64) Submitted: 11/30/07 6:29 AM

This seems like a good entry point given that the price has declined substantially over the last month despite reasonable progress in enrollment of phase III trials of Defibrotide. The company is definitely a one trick pony so it's way too risky to hold the stock through trial results. However, I an...More

Replies: 1 | Reply | Permalink

Top Bear Pitch

Recs

1

Gentium S.p.A. (ADR) (GENT)

Avatar cnikigreene (85.88) Submitted: 4/27/07 10:32 PM

THey are not on solid ground yet.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 2 of 2  

Recs

0

 (GENT)

Avatar Tankota (99.82) Submitted: 6/06/08 11:48 AM : Outperform Start Price: $9.99 GENT Score: -63.22

I used to read their magazines when I was a teenager. Good stiff. I mean stuff.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (GENT)

Avatar cnikigreene (85.88) Submitted: 4/27/07 10:32 PM : Underperform Start Price: $18.99 GENT Score: 66.01

THey are not on solid ground yet.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 2 of 2  

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackBroadpoint.AmTech 76.97 09/21/07 Outperform NS $23.50-92.13%-26.44%-65.69
TrackOppenheimer 81.36 08/21/07 Outperform NS $18.75-90.13%-21.95%-68.19

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD01 796ms